News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,724 Results
Type
Article (14896)
Company Profile (300)
Press Release (266522)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79851)
Career Advice (162)
Deals (13351)
Drug Delivery (39)
Drug Development (50723)
Employer Resources (31)
FDA (5839)
Job Trends (5167)
News (145130)
Policy (10072)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21766)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6033)
Artificial intelligence (258)
Autoimmune disease (111)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (231)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3129)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (218)
CDC (5)
Cell therapy (566)
Cervical cancer (14)
Clinical research (43683)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4322)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31656)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51717)
Executive appointments (621)
FDA (7586)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6613)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (191)
Immuno-oncology (39)
Indications (67)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7359)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6615)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2035)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26653)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15490)
Phase 2 (20289)
Phase 3 (12820)
Pipeline (3245)
Policy (90)
Postmarket research (853)
Preclinical (6547)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1447)
Recruiting (12)
Regulatory (9892)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (6)
Last 7 days (345)
Last 30 days (1296)
Last 365 days (17845)
2026 (1653)
2025 (18114)
2024 (20568)
2023 (22464)
2022 (26860)
2021 (27819)
2020 (23364)
2019 (16224)
2018 (11738)
2017 (13749)
2016 (11839)
2015 (14350)
2014 (10393)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18254)
Australia (3110)
California (7077)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39202)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5580)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1783)
North Carolina (825)
North Dakota (6)
Northern California (3474)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23346)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,724 Results for "gammadelta therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
December 22, 2025
·
6 min read
Press Releases
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
April 30, 2025
·
6 min read
Press Releases
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
April 29, 2025
·
7 min read
Drug Development
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones.
April 9, 2024
·
7 min read
Press Releases
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
April 1, 2025
·
2 min read
Pharm Country
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy 2024 Annual Meeting.
May 13, 2024
·
5 min read
Drug Development
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell platform, INB-300.
March 5, 2024
·
5 min read
Press Releases
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
March 4, 2025
·
8 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Pharm Country
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
LAVATherapeutics N.V. (Nasdaq:LVTX), a company in the clinical stage of immuno-oncology, is dedicated to advancing its unique Gammabody™ platform, which involves the development of bispecific gamma-delta T cell engagers.
June 1, 2023
·
5 min read
1 of 28,173
Next
